Renovaro
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 12
- Market Cap
- $106.1M
- Introduction
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Renovaro Partners with Nebul to Deploy NVIDIA SuperPOD for Breakthrough Disease
Renovaro collaborates with Nebul to advance early disease detection using NVIDIA DGX B200 systems with Blackwell GPUs, enabling faster processing of liquid biopsy samples and non-invasive cfDNA analysis.
Renovaro Announces Strategic Restructuring and Leadership Transition
Renovaro Inc. appoints David Weinstein as new CEO and replaces entire board with a five-member slate, supported by a supermajority of shareholders. The restructuring aims to optimize and commercialize RenovaroCube, the AI platform for multi-omics diagnostics in cancer early detection and patient monitoring. The new board comprises seasoned veterans in capital markets, governance, AI, biotechnology, and cancer detection, focusing on accelerating growth, commercialization, and long-term shareholder value.
RenovaroCube Presents Novel Insights on Non-Invasive Cancer
RenovaroCube presents research on Oxford Nanopore sequencing of cfDNA for detecting lung cancer CNAs, potentially reducing the need for invasive biopsies, at the Molecular Analysis for Precision Oncology Congress.
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society
RenovaroCube presents two scientific studies at ESMO Congress on September 15, 2024, showcasing AI-driven cancer detection using cfDNA fragmentomics and methylation patterns in blood samples, aiming to improve early detection and treatment options.
© Copyright 2025. All Rights Reserved by MedPath